344 IL - 13 /IL - 18 1 2 1 2 1 2 1 2 1 2 3 1 2 13 18 IL - 13 /IL - 18 10% / OVA /AL OH 3 5% 16 ~ 43 d 44 d ELISA BALF IL - 13 IL - 18 PCR RT - PCR IL - 13 IL - 18 mrna IL - 13 mrna 0. 01 IL - 18 mrna 0. 05 IL - 13 mrna 0. 01 IL - 18 mrna 0. 05 PCF SGPCG IL - 13 0. 01 PCF SGPCG IL - 18 mrna IL - 13 /IL - 18 P > 0. 05 PCF SGPCG IL - 13 IL - 18 mrna IL - 13 /IL - 18 P > 0. 05 IL - 13 mrna IL - 18 mrna IL - 13 /IL - 18 Th1 /Th2 IL - 13 /IL - 18 R562. 2 + 5 R285. 5 A 1673-6613 2013 04-0344 - 05 Intervention on IL - 13 /IL - 18 Imbalance in Asthma Mice Treated with the Therapy for Resolving Phlegm Removing Stasis and Soothing the Liver ZHANG Xin - guang 1 2 YU Jian - er 1 2 XUE Zheng 1 2 LI Li - qing 1 2 BAI Li 1 2 LIU Fei 3 WU Jie 1 2 1. Affiliated Municipal Chinese Medicine Hospital of Shanghai University of Traditional Chinese Medicine Shanghai 200071 2. Pediatrics Institute of Traditional Chinese Medicine Shanghai Academy of Traditional Chinese Medicine Shanghai 200071 3. Shanghai University of Traditional Chinese Medicine Shanghai 201203 Abstract Objective To explore the intervention on IL - 13 / IL - 18 imbalance in asthma mice treated with the therapy for resolving phlegm removing stasis and soothing the liver. Methods 10% OVA / AL OH 3 for sensitization and 5% egg albumen for excitation duplication were used to prepare bronchial asthma model in mice. Medication was given in the 16 th ~ 43 rd days of experiment. The materials were collected on the 44 th day. ELISA was adopted to detect IL - 13 and IL - 18 concentrations in BALF. RT - PCR was used to detect the expressions of IL - 13 and IL - 18 mrna in homogenate of lung tissue. Results IL - 13 concentration and its mrna expression of mice in the model group were increased significantly as compared with those in the blank group 0. 01 and IL - 18 concentration and its mrna expression were reduced significantly as compared with those in the blank group 0. 05. In each treatment group IL - 13 concentration and its mrna expression were reduced significantly as compared with those in the model group 0. 01 and IL - 18 concentration and its mrna expression were increased significantly 0. 05. The reducing of IL - 13 concentration in two herbal medicine groups was not good as the dexamethasone DXM group 0. 01. IL - 18 mrna expression and IL - 13 /IL - 18 ratio in the two herbal medicine groups were similar to those in DXM group P > 0. 05. The differences in IL - 13 and IL - 18 concentrations and No. 81202723 No. 81173302 ZYSNXD - CC - HPGC - JD - 005 1. 200071 2. 200071 3. 201203 Email 1066@ szy. sh. cn
345 their mrna expressions and IL - 13 /IL - 18 ratio were not significant between the two herbal medicine groups P > 0. 05. Conclusion The therapy for resolving phlegm removing stasis and soothing the liver reduces the increased IL - 13 concentration and its mrna expression in asthma mice and increases the reduced IL - 18 concentration and its mrna expression. The overall regulation of IL - 13 /IL - 18 ratio is similar to DXM. It is suggested that this therapy achieves the definite intervention on Th1 / Th2 immune imbalance relevant with neurogenic inflammation in asthma mice. Key words Therapy for Resolving Phlegm Removing Stasis and Soothing the Liver Asthma IL - 13 /IL - 18 1 h 2 h 5 1 h 2 h Ⅰ T T 2 95% helper type 1 Th1 Th1 /Th2 X = C2 V / C1 - C2 C1 Nerve Growth Factor NGF 95% C2 Th2 60% X V 13 Interleukin 13 IL - 13 Th1 IL - 24 h 1-18 3 4 6. 99 g ml - 1 2 / 5-8 PCF Th1 /Th2 1 2 2 2 2 2 1 2 2 5. 33 g 0. 75 mg IL - 13 IL 110702-18 0. 075 mg ml - 1 3. Th1 /Th2 20110209 IL - 13 IL - 18 ELISA RayBiotech IL - 13 DZE30477IL - 18 DZE30650 IL - 13 IL - 18 PCR Real time PCR RT - PCR ABI 1. Balb /c 18 ± 2 SCXK2008-0016 25 60% ~ 70% 2. 1 /1. 40 SGPCF PCF SGPCF 8 1 2 2 2 2 2 1 2 2 2 2 1 10% OVA /AL 9 db = da RB /RA WA /WB 1 /3 ml - 1 3 FR0421 K010372 g 3 ~ 5 40 4. MK3 Real - - time ABI 7500 Sequence Detection System ABI - 7500 OH 3 1 ml 1 15 db B da 2 5 L A WA WB 5% OVA RB RA 40 min 1 7 d 30 kg 10 10 6
346 20% 0. 01 BALF 10% EOS IgE 0. 01 1. IL - 13 IgE EOS 1 IL - 13 BALF ELISA 0. 01 2. 1 16 ~ 43 0. 4 ml 20 g - 1 2 44 0. 05 1 BALF 2 1-80 2 10% HE 1. 0 cm l. 0 cm 0. 2 cm 3 ELISA BALF IL - 13 IL - 18 IL - 13 IL - 18 RT - PCR 29 1 2. 14% 23. 55% 27. 1% - 2. 69% HE PCF SGPCF 0. 01 PCF SGPCG 0. 01 PCF SGPCG P > BALB /c BALF IL - 13 x ± s ng L - 1 n IL - 13 8 5. 29 ± 0. 46 8 23. 57 ± 0. 74 a 8 8. 64 ± 0. 60 b PCF 8 11. 94 ± 0. 95 bc SGPCF 8 12. 15 ± 0. 60 bc a P < 0. 01 b P < 0. 01 2 IL - 13 mrna RT - PCR SPSS18 One - 0. 01 PCF SGPCF Way Anova Homogeneity - of - variance 0. 01 PCF P > 0. 05 SGPCF LSD 0. 01 PCF SGPCG Games Howell 0. 05 P > 0. 05 2 2 BALB /c IL - 13 mrna x ± s % n IL - 13 8 0. 05 ± 0. 03 8 3. 88 ± 1. 55 a 8 0. 13 ± 0. 03 b PCF 8 0. 17 ± 0. 09 b SGPCF 8 0. 27 ± 0. 06 bc a P < 0. 01 b P < 0. 01 0. 01 2. IL - 18 1 IL - 18 BALF ELISA 0. 01 17. 06 PCF SGPCF 7. 20 0. 01 0. 01 PCF SGPCG
347 0. 01 PCF SGPCG P > 0. 05 3 3 BALB /c BALF IL - 18 x ± s ng L - 1 n IL - 18 8 46. 34 ± 4. 19 8 9. 74 ± 2. 83 a 8 40. 82 ± 3. 77 b PCF 8 26. 97 ± 2. 23 bc SGPCF 8 27. 18 ± 1. 66 bc a P < 0. 01 b P < 0. 01 2 IL - 18 mrna RT - PCR 0. 05 PCF SGPCF 20 80 0. 05 0. 01 PCF SGPCG P > 0. 05 PCF SGPCG P > 0. 05 4 4 BALB /c IL - 18 mrna x ± s % n IL - 18 8 17. 20 ± 12. 58 8 0. 18 ± 0. 11 a 8 4. 94 ± 2. 87 b PCF 8 1. 97 ± 0. 67 c SGPCF 8 1. 77 ± 1. 13 b a P < 0. 05 b P < 0. 3. IL - 13 mrna /IL - 18 NGFmRNA mrna 0. 05 NGF PCF SGPCF P Th1 Th2 < 0. 05 PCF SGPCG Th1 /Th2 11 P > 0. 05 PCF SGPCG GATA - 3 12 P > 0. 05 5 5 BALB /c BALF IL - 13 /IL - 18 x ± s n IL - 13 /IL - 18 8 0. 01 ± 0. 01 8 28. 08 ± 19. 85 a 8 0. 03 ± 0. 03 b PCF 8 0. 12 ± 0. 11 b SGPCF 8 0. 25 ± 0. 23 b a P < 0. 05 b P < 0. NGF TrkA 1 Th1 /Th2 IL - 13 IL - 18 NGFmRNA Th1 /Th2 Th2 IL - 13 mrna Th1 IL - 18 NGFmRNA Th1 /Th2 IL - 13 IL - 18 Th1 /Th2. 13. 2009 377
377 3 % % 3 32 59. 26 15 27. 78 7 12. 96 87. 04 24 22 40. 74 17 31. 48 15 27. 78 72. 22 a 3 33 61. 11 15 27. 78 6 11. 11 88. 89 24 45 83. 33 6 11. 11 3 5. 56 94. 44 ab 3 a P < 0. 05 b P < 0. 1. 2009 4-5 6 3 4.. 2010 5. 2007 6 7 42-45.. 2009 44 12 977-978. 2. 2004. 2005 40 3 166-167. 24 4 280... 1989. 16 9 901-903. 7.. 13 2 129-130 132... 2004 20 5 569-570... 2007 26 12 2013-03 - 02 347 3 5 35-38. 2Braun A Lommatzsch M Renz H. The role of neumtrophins in allergic bronchial asthma. Clin Exp Allergy 2000 30 2 178-186. 3. - 13 IL - 13-18.. 2006 5 11 4-6. IL - 18 mrna NGF mr- 9. M. NA. 2010 35 8 1208 2001 357. - 1211. 10. M. 2. 4. 30 2006 119-120.. 2008 4 1 14-16. 11. 5. Th1 /Th2. Th1 /Th2. 2006 2 1 23-26. 2010 24 2 109-111. 6. 12. Thl /Th2 γ 4. 2012 10. 2008 12 5 595-597. 7 807-813. 7. T - bet /GATA - 3. 2012 5 974-977. 8. 2013-02 - 04